Welcome to our dedicated page for Day One Biopharmaceuticals SEC filings (Ticker: DAWN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Day One Biopharmaceuticals filings document the company's transition from a Nasdaq-listed oncology biopharmaceutical issuer to an acquired company with Exchange Act deregistration filings. The record includes Form 25 removal of DAWN common stock from Nasdaq and Form 15 certification covering termination of registration or suspension of reporting duties after the acquisition.
Day One's 8-K filings report material agreements, tender-offer and merger-related events, shareholder voting and governance matters, capital-structure disclosures, and financial-statement exhibits. Other disclosures cover OJEMDA (tovorafenib), U.S. product revenue reporting, Ipsen's ex-U.S. commercialization rights, and clinical or regulatory updates for pediatric low-grade glioma and rare-cancer programs.
A holder of DAWN common stock filed a Rule 144 notice to sell up to 5,814 shares on NASDAQ through Morgan Stanley Smith Barney LLC, with an indicated aggregate market value of 67,447.63. The filing lists total common shares outstanding as 102,675,502.
The shares to be sold were acquired on 02/15/2026 as restricted stock from the issuer, with the nature of payment described as not applicable. By signing the notice, the seller represents that they are not aware of any material adverse, nonpublic information about the issuer’s current or prospective operations.
An affiliate of DAWN filed a Rule 144 notice to sell 6,395 shares of common stock, with an aggregate market value of $74,187.76, through Morgan Stanley Smith Barney LLC on NASDAQ around February 17, 2026.
The shares were acquired as restricted stock from the issuer on February 15, 2026. The filing lists 102,675,502 shares of the issuer’s common stock outstanding, providing context for the planned sale size.
Day One Biopharmaceuticals shareholder Vestal Point Capital filed a Schedule 13G disclosing a passive stake in the company. Vestal Point Capital and Ryan Wilder report beneficial ownership of 5,200,000 shares of common stock, representing 5.1% of the class.
The ownership percentage is based on 102,675,502 shares of common stock outstanding as of October 31, 2025, as reported in Day One’s Form 10-Q. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
FMR LLC has filed an amended Schedule 13G reporting beneficial ownership of 5,717,007.68 shares of Day One Biopharmaceuticals Inc. common stock, representing 5.6% of the outstanding class as of 12/31/2025. FMR LLC reports sole voting power over 5,702,209.00 shares and sole dispositive power over 5,717,007.68 shares, with no shared voting or dispositive power. Abigail P. Johnson is also listed as a reporting person, with sole dispositive power over 5,717,007.68 shares and no voting power. The securities are stated to be held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Day One Biopharmaceuticals granted new equity awards to its COO and CFO, Charles N. York II. On January 30, 2026, he received a stock option covering 188,000 shares of common stock at an exercise price of $11.16 per share, vesting in equal monthly installments over 48 months starting February 28, 2026.
He also received 126,000 Restricted Stock Units (RSUs), each representing one share of common stock upon settlement. These RSUs vest in 16 equal quarterly installments on February 15, May 15, August 15 and November 15, subject to continued service, and either vest or are canceled before vesting rather than expiring on a set date.
Day One Biopharmaceuticals granted new equity awards to its Head of Research and Development, Michael Vasconcelles, effective January 30, 2026. He received a stock option for 171,000 shares of common stock at an exercise price of $11.16, plus 114,000 Restricted Stock Units (RSUs).
The option vests as to 1/48 of the total shares each month starting February 28, 2026, contingent on continued service. Each RSU represents one share of common stock and vests 1/16 of the total award quarterly on February 15, May 15, August 15 and November 15, also subject to continued service. RSUs either vest or are canceled; they do not have an expiration date.
Day One Biopharmaceuticals reported new equity awards to its Chief Executive Officer Jeremy Bender. On January 30, 2026, he received a stock option for 355,000 shares of common stock at an exercise price of $11.16 per share, expiring on January 29, 2036. The option vests in equal monthly installments of 1/48th of the total from February 28, 2026, as long as he continues serving the company.
He was also granted 237,000 Restricted Stock Units (RSUs), each representing one share of common stock upon settlement. These RSUs vest in 1/16th increments on February 15, May 15, August 15 and November 15 in quarterly installments, contingent on continued service. The RSUs do not have a traditional expiration date; they either vest on schedule or are canceled if conditions are not met.
Day One Biopharmaceuticals granted its Chief Commercial Officer, Lauren Merendino, new equity awards dated January 30, 2026. She received a stock option for 110,000 shares of common stock at an exercise price of $11.16 per share. The option vests in 1/48th monthly, starting February 28, 2026, as long as she continues providing service on each vesting date.
Merendino also received 74,000 Restricted Stock Units (RSUs). Each RSU represents a right to one share of common stock upon settlement and vests in 1/16th quarterly installments on February 15, May 15, August 15 and November 15, subject to continued service. RSUs either vest or are canceled before the vesting date and do not have a traditional expiration date.
Day One Biopharmaceuticals’ General Counsel and Secretary, Adam Dubow, reported new equity awards. On January 30, 2026, he received a stock option for 105,000 shares of common stock at a $11.16 exercise price, held directly. The option vests in equal monthly installments over 48 months starting February 28, 2026, contingent on continued service.
He was also granted 70,000 Restricted Stock Units (RSUs), each representing one share of common stock upon settlement. The RSUs vest in 16 quarterly installments on February 15, May 15, August 15, and November 15, subject to ongoing service, and either vest or are canceled before vesting.
Day One Biopharmaceuticals, Inc. filed a report describing preliminary, unaudited net product revenue for OJEMDA for the fourth quarter and full year ended December 31, 2025, along with its cash, cash equivalents and short-term investments as of that same date. These figures are estimates and may change once the company completes its year-end financial close and external reporting.
The company also outlined 2026 priorities, including plans to complete enrollment in the pivotal Phase 3 FIREFLY-2 trial of tovorafenib as a front-line therapy for pediatric low-grade glioma in the first half of 2026, share initial Phase 1a data for DAY301 in the second half of 2026, and deliver Phase 1 clinical data for the Emi-Le program by mid-2026. Day One noted that it will present at the 44th Annual J.P. Morgan Healthcare Conference and furnished a press release and presentations as exhibits, while emphasizing that the information is being furnished, not filed, for securities law purposes.